Boehringer Ingelheim
勃林格殷格翰
Boehringer Ingelheim is the world's largest private pharmaceutical company, per a 2023 Yunqi Capital report on its partnership with 3D-printed drug developer Triastek . The German drugmaker has been active in China's innovation ecosystem, collaborating with local startups on drug formulation R&D—most notably signing an agreement with Triastek to accelerate new drug development using 3D printing technology for novel drug molecules , and maintaining ongoing partnerships across product and technology solutions with the Nanjing-based firm . The company also appeared in a 2020 Frees Fund gene therapy event as a cross-boundary R&D presence in China .
AI-generated — may contain errors, please verify.
Coverage
Over $1.2 Billion in Total Value: Triastek Announces First-Ever Technology Platform International Collaboration in Chinese Pharmaceutical History with BioNTech | Yunqi Capital
Empowering Digital Transformation in Pharmaceutical Development
"Triastek" Closes 150 Million Yuan Pre-C Round to Accelerate Commercialization of 3D-Printed Drugs | Yunqi Capital
Pioneering a New Era of Intelligent Drug Discovery
How Can a "3D Printer" Boost Productivity in the Pharmaceutical Industry? | The B-Side of Entrepreneurship
Take the hard, meaningful path
"Triastek" Partners with World's Largest Private Pharmaceutical Company: 3D Printing Technology Accelerates New Drug R&D | Yunqi Tech π
Triastek Enters Partnership with Boehringer Ingelheim
Riding the Gene Therapy Wave | Frees Fund
From Willow Bark to "God's Scalpel" — A Brief History of Drug Development
